Alternatives to Statins: Your Options Compared

What are the alternatives to statins?

The main alternatives to statins are other prescription medicines that lower LDL cholesterol through different routes, and several have trials showing fewer heart attacks and strokes. If statins gave you trouble, you have more options than ever. Some people do well on a different statin or a lower dose. Others need a non-statin prescription: ezetimibe, bempedoic acid (Nexletol), a PCSK9 inhibitor (an injection, including the once-monthly Lerochol, or the new daily pill Lipfendra), or inclisiran (Leqvio). Supplements and lifestyle changes help some people, but they rarely close a large gap on their own.

Start with one question: did the statin cause the symptoms?

How do I know if I am truly statin intolerant?

Often the statin turns out to be innocent, so check that first. Statin intolerance means side effects from a statin, most often muscle aches, that get better when the dose is lowered or the drug is stopped. Some people truly have it, though fewer than it seems.

Two blinded trials tested this directly. In both, people who had quit statins because of muscle symptoms took a statin during some months and an identical-looking placebo during others, without knowing which was which.

• SAMSON (60 patients, UK) found symptom scores were nearly the same on the statin and on placebo. About 90% of the symptom burden people felt on the statin also showed up on the dummy pill. We cover this trial in more depth in our statin side effects guide.
• StatinWISE (200 patients in UK primary care) found no overall difference in muscle symptom scores between atorvastatin 20 mg and placebo. Two thirds of the people who finished the trial decided to restart a statin long term.

A huge pooled analysis of 19 large blinded trials, about 124,000 people, reached a similar conclusion. In the first year, only about 1 in 15 reports of muscle pain or weakness among people taking a statin was caused by the statin.

Your aches were real, but the statin often wasn't the cause, and stopping it removes the protection while the pain stays.

Retrying a different statin or dose

Most people who stop a statin over side effects can take one again, often a different statin or a lower dose. Statins differ in how they are processed by the body and how they interact with other medicines. Practical ways to retry include:

• A different statin, such as switching from simvastatin or atorvastatin to rosuvastatin or pravastatin
• A lower dose, sometimes combined with a non-statin to make up the difference
• Less frequent dosing, such as every other day or a few times a week, which the NLA lists as a reasonable strategy

In a Boston study of more than 100,000 patients, about 92% of people who were restarted on a statin after a suspected side effect were still taking one a year later.

A retry works best with a plan: a defined timeline, a symptom log, and a fallback if it does not work.

What are the non-statin cholesterol-lowering medications?

The proven non-statin prescriptions are ezetimibe, bempedoic acid, PCSK9 inhibitors, and inclisiran. They range from about an 18% LDL drop (ezetimibe) to 50 to 60% (PCSK9 inhibitors), and several can be combined.

Ezetimibe

Ezetimibe blocks cholesterol absorption in the gut. On its own it lowered LDL by about 18% on average in the studies in its FDA label (DailyMed), and it adds to whatever a statin is already doing. You take it once a day as a generic pill, and it causes very few side effects. In the IMPROVE-IT trial of 18,144 people recently hospitalized for a heart attack or unstable chest pain, adding ezetimibe to a statin reduced cardiovascular events.

Bempedoic acid (Nexletol)

Bempedoic acid works in the liver, one step upstream from where statins act. The liver activates it and muscle doesn't, so it causes few muscle side effects. Our Nexletol (bempedoic acid) guide walks through the mechanism step by step and explains how the Nexlizet combination pill adds ezetimibe.

The CLEAR Outcomes trial makes it especially relevant for statin-intolerant patients. It enrolled nearly 14,000 people who could not or would not take statins because of side effects. Over about 3.4 years, bempedoic acid lowered LDL about 21% more than placebo and reduced major cardiovascular events by 13%. Heart attacks fell by 23%. Gout (3.1% vs 2.1%) and gallstones (2.2% vs 1.2%) were somewhat more common on the drug.

PCSK9 inhibitors

PCSK9 is a protein that destroys the liver's LDL receptors. Blocking it leaves more receptors to pull LDL out of the blood. These drugs are the strongest add-on we have, and they work whether or not you take a statin.

• Evolocumab (Repatha) and alirocumab (Praluent) are self-injected every 2 weeks or once a month. Evolocumab lowered LDL by 59% in the FOURIER trial and reduced cardiovascular events, and the VESALIUS-CV trial (2025) showed benefit in high-risk people who had never had a heart attack or stroke. Amgen also sells Repatha directly through AmgenNow for $239 a month (as of October 2026); see Repatha cost.
• Enlicitide (Lipfendra) is the first PCSK9 inhibitor in pill form, approved by the FDA in July 2026. It lowered LDL by 56% versus placebo in its main trial, and Merck's list price is roughly $315 a month before insurance (as of October 2026). You take it once daily on an empty stomach and wait 30 minutes before eating. Its outcomes trial is still running. See our Lipfendra guide for details.
• Lerodalcibep (Lerochol) is a self-injection given once a month, approved by the FDA in December 2025 and launched in the US in May 2026. It lowered LDL by about 56% versus placebo over a year in its pivotal trial, and it can be kept at room temperature for up to 3 months. No outcomes trial has reported yet. LIB Therapeutics sells it directly to patients for $199 a month (as of its May 2026 launch), and an autoinjector pen approved in August 2026 is expected by January 2027. See our Lerochol guide.

Insurers usually require documented statin and ezetimibe trials before covering these. More in our PCSK9 inhibitors guide, or see how a PCSK9 inhibitor prescription works with us.

Inclisiran (Leqvio)

Inclisiran uses a different approach, called small interfering RNA, to switch off PCSK9 production in the liver. A healthcare professional injects it in a clinic: at the start, at 3 months, and then every 6 months. It lowered LDL by about 50% in its phase 3 trials. As of October 2026, its large outcomes trials, ORION-4 and VICTORION-2 PREVENT, have not reported results. We're working with infusion centers to offer it; see our Leqvio guide.

Which non-statin option lowers cholesterol the most?

PCSK9 inhibitors lower LDL the most (about 50 to 60%), while ezetimibe and bempedoic acid each lower it about 18 to 21% and cost less. Here is how they line up:

Percentages are averages from clinical trials and are not additive in a simple way. Combinations, like ezetimibe plus bempedoic acid, or a PCSK9 inhibitor plus ezetimibe, are common and often needed.

Natural alternatives to statins: what the evidence shows

Natural alternatives lower LDL modestly at best, and none has been shown to prevent heart attacks the way prescription options have. Plenty of thoughtful people prefer to start with supplements, so here is how they hold up.

Red yeast rice. It comes closest to a natural statin because it contains monacolin K, which is chemically identical to lovastatin. Products with meaningful amounts of monacolin K do lower LDL. Quality varies widely. When researchers tested 28 US brands, none listed the monacolin K amount on the label, two had none, and the rest varied more than 60-fold. A 2021 analysis of 37 products found that only one had levels of citrinin, a contaminant that can harm the kidneys, below the European Union's limit. The FDA treats red yeast rice with more than trace monacolin K as an unapproved drug. If a statin caused you side effects, red yeast rice can cause the same ones. (NIH NCCIH)

Plant sterols and stanols. Found in fortified foods and supplements, they block some cholesterol absorption. A meta-analysis of 124 studies found 0.6 to 3.3 grams a day lowered LDL by about 6 to 12%. The effect is modest and real.

Soluble fiber. Oats, beans, barley, and psyllium lower LDL modestly and are good for you in other ways.

Bergamot and berberine. Small studies suggest some cholesterol lowering, but trials are limited, products vary, and there is no evidence yet that either prevents heart attacks.

None of these supplements has outcomes trials showing fewer heart attacks, so they can play a supporting role alongside proven treatment but don't replace it. Tell your care team what you take, since some interact with prescriptions.

How to lower cholesterol without statins: lifestyle

Lifestyle lowers LDL for most people and is the foundation for everyone, statin or not, though it rarely closes a large gap alone:

• Swap saturated fat (fatty meats, butter, full-fat dairy) for unsaturated fats like olive oil, nuts, and fish
• Eat more soluble fiber and plant foods
• Lose weight if you need to, and move most days
• Don't smoke, and keep blood pressure and blood sugar in range

How much this lowers LDL varies a lot from person to person. If your high cholesterol is largely genetic, diet often moves the number less than you would hope, despite real effort. Our guide on whether high cholesterol is genetic explains why.

What are the alternatives to statins for women, including in pregnancy and breastfeeding?

Women have the same non-statin options as men, with extra planning around pregnancy and breastfeeding. Most lipid-lowering medicines, statins included, stop for pregnancy and breastfeeding, and the details vary by drug. If you could become pregnant, plan to become pregnant, or are breastfeeding, talk with your clinician before you start, stop, or switch a cholesterol medicine.

Statins. In July 2021 the FDA asked statin makers to remove the strongest warning (a contraindication) against use in pregnancy, and said most patients should still stop a statin once they learn they are pregnant. The FDA also said treating high cholesterol is generally not necessary during pregnancy, and that a small group at very high risk, such as people with homozygous familial hypercholesterolemia or a prior heart attack or stroke, can weigh the decision case by case. For people who are not pregnant but could become pregnant, the FDA says statins remain appropriate. Accidental exposure in early pregnancy, before you knew, is unlikely to harm the baby, and observational studies found no increase in birth defects after adjustment. For breastfeeding, the FDA says statins may pass into breast milk and breastfeeding is not recommended while taking one (FDA Drug Safety Communication, 2021).

What the 2018 ACC/AHA guideline adds. As summarized by the National Lipid Association, the guideline advises counseling sexually active women of childbearing age on statins to use reliable contraception, stopping the statin one to two months before trying to conceive (or as soon as a pregnancy is found), and holding off restarting until pregnancy and breastfeeding end (NLA summary). The guideline also lists premature menopause (before age 40) and pregnancy complications such as preeclampsia as factors that raise long-term cardiovascular risk and can tip a decision toward a statin (guideline text, Table 6). Share your pregnancy history with your clinician for that reason.

Non-statin medicines, per their FDA labels:

• Ezetimibe: pregnancy data are insufficient to judge risk, and the label says to use it in pregnancy only if the potential benefit justifies the potential risk to the fetus. It also says there is no information on ezetimibe in human milk, and to use it while nursing only if the benefit justifies the risk (DailyMed).
• Bempedoic acid (Nexletol): the label says to stop it once pregnancy is recognized unless the benefit outweighs the fetal risk. A small study of women taking it found it in breast milk at low estimated infant doses, and the label asks you and your clinician to weigh the need for treatment against the benefits of breastfeeding (DailyMed).
• Repatha and Praluent: pregnancy data are insufficient, and both antibodies, like other IgG antibodies, cross the placenta. Neither label has information on milk levels, though the labels cite published data suggesting breast milk antibodies do not enter an infant's circulation in substantial amounts. Both ask you to weigh breastfeeding benefits against the need for the medicine (Repatha label, Praluent label).
• Leqvio (inclisiran): the label says to stop it when pregnancy is recognized, because it may cause fetal harm based on how it works. No human data exist. The label reports no information on milk presence in people, and says low milk levels are considered unlikely to harm an infant (DailyMed).

Labels change, so confirm the current wording with your pharmacist. Lipfendra and Lerochol are too new for this guide to cover their pregnancy and breastfeeding labels, so check those directly if you are considering them. Bring up pregnancy plans at your first visit. A clinician can time any medicine change around conception and breastfeeding and keep your numbers in a safe range.

Enter your LDL and goal to see what each medicine could do on average.

What should I do if I stopped taking statins?

Get fresh labs, write down what happened, and pick a path. If you have already stopped, you're in good company.

How Preval Health helps

Our protocols cover statin intolerance. A board-certified preventive cardiologist wrote Preval's treatment protocols, and licensed clinicians through our partner telehealth network deliver the care.

The protocol confirms whether a statin is truly the cause, offers a structured retry when it makes sense, and moves through non-statin options step by step, with labs every quarter to check progress. Every trial and lab value goes into your record. Preval runs as a cash practice at $99 a month for care, with medicines at cash prices and no insurance paperwork. Learn more about our statin intolerance program.